Return to homepagePandemic Pact

Identifying inhibitors of the bacterial peptidyl-tRNA hydrolase

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 1R21AI196497-01

Grant search

Key facts

  • Disease

    Bacterial infection caused by Klebsiella pneumonia, Other
  • Start & end year

    2026
    2028
  • Known Financial Commitments (USD)

    $440,908
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR Paul Carlier
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF ILLINOIS AT CHICAGO
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Peptidyl-tRNA hydrolase (Pth) is an essential bacterial enzyme critical for protein synthesis and whose inactivation leads to cell death. Pth recycles peptidyl-tRNAs that prematurely dissociate from the translated ribosome. Additionally, Pth is involved in rescuing the large ribosomal subunit that remains associated with peptidyl-tRNA after the splitting of the stalled ribosome. It may also contribute to other ribosome rescue mechanisms. Despite its essentiality, efforts to identify Pth inhibitors have been hindered by challenges in generating suitable substrates for high-throughput screening (HTS). To address this, we designed an oligonucleotide-based Pth substrate that mimics peptidyl-tRNA and used it to develop and validate an HTS assay based on the Förster resonance energy transfer (FRET). Limited preliminary studies have identified several compounds with inhibitory activity against Pth from Escherichia coli and Klebsiella pneumoniae. This proposal aims to advance Pth inhibitor development by synthesizing and optimizing derivatives of the most potent hits with sub-micromolar IC50 values to enhance their activity against K. pneumoniae Pth and improve cellular uptake. Concurrently, we will expand the screening campaign to identify novel inhibitor scaffolds. The interaction of these compounds with Pth will be studied by SPR and X-ray crystallography, to guide medicinal chemistry optimization. In addition, we will characterize their mechanisms of action, cellular targets, effects on protein synthesis, and potential resistance mechanisms. The anticipated outcome is the identification of a lead inhibitor scaffold suitable for preclinical development as a foundation for a novel antibiotic platform.